MIDAZOLAM HYDROCHLORIDE - Generic Drug Details

What are the generic sources for midazolam hydrochloride and what is the scope of freedom to operate?

Midazolam hydrochloride is the generic ingredient in six branded drugs marketed by Apothecon, Baxter Hlthcare Corp, Bedford, Ben Venue, Epic Pharma Llc, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Hospira, Hospira Inc, Igi Labs Inc, Intl Medicated, Intl Medication, Micro Labs, Ph Health, Rising, Onesource Specialty, HLR, Rafa Labs Ltd, MMT, Padagis Us, Pai Holdings, Pharm Assoc, Sun Pharm Inds Ltd, and Roche, and is included in forty NDAs. Additional information is available in the individual branded drug profile pages.

Twenty-two suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for MIDAZOLAM HYDROCHLORIDE

US Patents:	0
Tradenames:	6
Applicants:	25
NDAs:	40
Finished Product Suppliers / Packagers:	22
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1,722
Patent Applications:	2,616
What excipients (inactive ingredients) are in MIDAZOLAM HYDROCHLORIDE?	MIDAZOLAM HYDROCHLORIDE excipients list
DailyMed Link:	MIDAZOLAM HYDROCHLORIDE at DailyMed

Recent Clinical Trials for MIDAZOLAM HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Novartis Pharmaceuticals	PHASE1
Anesthesia Clinical Trials Unit (Department of Anesthesia and Pain Management)	PHASE3
Women's College Hospital	PHASE3

See all MIDAZOLAM HYDROCHLORIDE clinical trials

Generic filers with tentative approvals for MIDAZOLAM HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		EQ 5MG BASE/ML	INJECTABLE;INJECTION

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for MIDAZOLAM HYDROCHLORIDE

Drug Class

Benzodiazepine

Medical Subject Heading (MeSH) Categories for MIDAZOLAM HYDROCHLORIDE

Adjuvants, Anesthesia

Anesthetics, Intravenous

Anti-Anxiety Agents

GABA Modulators

Hypnotics and Sedatives

Anatomical Therapeutic Chemical (ATC) Classes for MIDAZOLAM HYDROCHLORIDE

N05CD	Benzodiazepine derivatives
N05C	HYPNOTICS AND SEDATIVES
N05	PSYCHOLEPTICS
N	Nervous system

US Patents and Regulatory Information for MIDAZOLAM HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rising	MIDAZOLAM HYDROCHLORIDE	midazolam hydrochloride	INJECTABLE;INJECTION	075494-002	Jun 30, 2000	AP	RX	No	No
Hikma	MIDAZOLAM HYDROCHLORIDE	midazolam hydrochloride	INJECTABLE;INJECTION	075324-002	Jun 20, 2000	AP	RX	No	No
Hikma	MIDAZOLAM HYDROCHLORIDE	midazolam hydrochloride	SYRUP;ORAL	075873-001	Apr 30, 2002	AA	RX	No	Yes
Hospira	MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE	midazolam hydrochloride	INJECTABLE;INJECTION	075857-001	Jul 22, 2002	AP	RX	No	Yes
Hikma	MIDAZOLAM HYDROCHLORIDE	midazolam hydrochloride	INJECTABLE;INJECTION	075421-002	Jun 20, 2000	AP	RX	No	No
Ph Health	MIDAZOLAM HYDROCHLORIDE	midazolam hydrochloride	INJECTABLE;INJECTION	078141-001	May 30, 2008		DISCN	No	No

Expired US Patents for MIDAZOLAM HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Hlr	VERSED	midazolam hydrochloride	INJECTABLE;INJECTION	018654-002	May 26, 1987	4,280,957*PED
Hlr	VERSED	midazolam hydrochloride	INJECTABLE;INJECTION	018654-001	Dec 20, 1985	4,280,957*PED
Roche	VERSED	midazolam hydrochloride	SYRUP;ORAL	020942-001	Oct 15, 1998	4,280,957*PED

Market Dynamics and Financial Trajectory for Midazolam Hydrochloride

Last updated: January 25, 2026

Executive Summary

Midazolam Hydrochloride, a short-acting benzodiazepine, is extensively used as an anesthetic, sedative, and anticonvulsant. Its global market has demonstrated steady growth driven by rising demand in healthcare, particularly in anesthesia and intensive care applications. The market is influenced by factors such as evolving clinical practices, regulatory approvals, and the introduction of generic formulations. This report provides a detailed analysis of the market dynamics, competitive landscape, and financial outlook for Midazolam Hydrochloride, emphasizing key trends, valuation, and future opportunities.

---

Market Overview

Parameter	Details
Therapeutic Class	Benzodiazepine sedative, anxiolytic, anticonvulsant
Primary Uses	Anesthesia induction, sedation in ICU, anticonvulsant in status epilepticus
Global Market Size (2022)	Approximately USD 150 million
Projected CAGR (2023-2028)	4.2% (compound annual growth rate)
Key Regions	North America, Europe, Asia-Pacific

---

Market Drivers

1. Increasing Adoption in Critical Care and Anesthesia

Midazolam’s rapid onset and short duration are ideal for procedural sedation and ICU sedation, boosting demand in hospitals globally. The rising prevalence of surgeries, including minimally invasive and outpatient procedures, further fuels usage.

2. Growing Incidence of Acute and Chronic Conditions

The global increase in neurological disorders and the need for effective anxiolytics have escalated Midazolam’s use as an anticonvulsant, especially in emergency settings.

3. Regulatory Approvals and Healthcare Infrastructure

Stringent regulatory requirements in emerging markets create opportunities for approved formulations, supported by investments in healthcare infrastructure.

4. Rise in Geriatric Population

An aging population increases procedural interventions requiring sedation, thereby expanding market scope.

---

Market Restraints

Restraint	Details
Regulatory Challenges	Stringent approval processes and control measures due to abuse potential
Availability of Alternatives	Use of other benzodiazepines like lorazepam, diazepam
Controlled Substance Status	Class IV (US), Schedule IV (WHO), leading to strict distribution and control practices
Generic Competition	Entry of cost-competitive generic formulations compresss pricing

---

Competitive Landscape

Company	Key Products	Market Share (Est.)	Strategic Initiatives
Pfizer	Midazolam (marketed as Versed)	35%	Portfolio expansion, global distribution network
Hospira (Pfizer spin-off)	Generic Midazolam products	25%	Focused on biosimilar and generic markets
Recordati	Midazolam injection	15%	Licensing agreements, regional expansion
Other Companies	Multiple regional generics	25%	Cost leadership, regional regulatory approvals

---

Financial Trajectory: Revenue and Profitability

Year	Estimated Revenue (USD million)	CAGR	Key Factors
2022	150	--	Mature market with stable demand
2023	156	4.0%	Post-pandemic recovery, new approvals
2024	162	4.2%	Increased hospitalizations, expanded use
2025	169	4.3%	Broadened applications, emerging markets
2026	177	4.4%	Volume growth, price stabilization

Revenue Breakdown by Region (2022)

Region	Revenue (USD million)	Market Share	Key Growth Drivers
North America	60	40%	Healthcare infrastructure, procedural volume
Europe	45	30%	Clinical practice guidelines, aging population
Asia-Pacific	30	20%	Rapid healthcare expansion, regulatory approvals
Rest of World	15	10%	Growing access, affordable generics

---

Regulatory and Policy Influences

Approvals and Reimbursement Policies

• FDA (USA): Midazolam in injectable form broadly approved; controlled substance regulations apply.
• EMA (Europe): Similar approvals with strict controls.
• Emerging Markets: Increasing approvals, though pricing and reimbursement vary significantly.

Impact of Controlled Substance Regulations

Stringent controls limit distribution channels but also reduce misuse, influencing supply chain dynamics and price stability.

---

Future Market Opportunities

Opportunity	Details
Generic Expansion	Increasing market penetration with biosimilars and generics in large markets
New Indications	Investigating role in novel sedation protocols and pediatric anesthesia
Combination Therapy	Potential formulations with other anesthetics or analgesics
Emerging Markets	Rapid healthcare infrastructure growth in Asia and Africa

---

Comparative Analysis with Similar Sedatives

Drug	Key Features	Market Penetration	Regulatory Status	Main Use Cases
Midazolam	Short-acting, versatile	Leading	Approved globally	ICU sedation, anesthesia, seizures
Lorazepam	Longer duration	Moderate	Approved	Anxiety, status epilepticus
Diazepam	Long-acting	Moderate	Widely approved	Seizures, muscle spasms
Propofol	Rapid onset, short duration	High	Schedule-controlled	General anesthesia

FAQs on Midazolam Hydrochloride Market

1. What are the key factors influencing the pricing of Midazolam Hydrochloride?

Pricing is affected by regulatory controls, generic competition, production costs, and regional healthcare reimbursement policies. As a controlled substance, strict distribution limits also influence market dynamics.

2. How does the shift toward outpatient procedures affect the market?

The trend toward minimally invasive outpatient procedures increases demand for short-acting, rapidly reversible sedatives like Midazolam, expanding its application base.

3. What is the future outlook for generic Midazolam formulations?

Generics are expected to dominate growth due to cost advantages, especially in emerging markets where affordability is critical. Patent expirations in key regions further accelerate this trend.

4. Are there notable clinical innovations affecting Midazolam's market?

Developments in sedation protocols and combination therapies can extend the drug's application, potentially increasing demand for specific formulations tailored to new clinical practices.

5. What regulatory challenges does Midazolam face globally?

Stringent controls due to its abuse potential complicate manufacturing, distribution, and prescribing practices, especially in countries with strict opioid and sedative regulations.

---

Key Takeaways

• Steady Growth Trajectory: Expected CAGR of 4.2% driven by expanding healthcare infrastructure and procedural volume globally.
• Market Leaders: Pfizer’s Versed maintains dominant market share through extensive distribution networks, complemented by increasing generic competition.
• Regional Variations: North America leads in revenues due to high procedural volumes; Asia-Pacific presents significant growth potential.
• Regulatory Environment: Strict control regulations influence supply chains and pricing strategies, with opportunities arising in emerging markets.
• Innovation and Expansion: Future growth hinges on new indications, combination therapies, and leveraging generic markets.

---

References

[1] Market research reports (e.g., Research and Markets, MarketsandMarkets).
[2] Public regulatory documents (FDA, EMA).
[3] Annual reports from leading pharmaceutical companies.
[4] Industry publications such as GlobalData and IQVIA.

Note: All figures are estimates based on publicly available data as of 2022-2023 and are subject to change based on market developments.

---

Disclaimer: This document is for informational purposes only and does not constitute investment advice.